Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.

Autor: Maarten van Dinther, Juan Zhang, Stella E Weidauer, Verena Boschert, Eva-Maria Muth, Achim Knappik, David J J de Gorter, Puck B van Kasteren, Christian Frisch, Thomas D Mueller, Peter ten Dijke

Publikováno v: PLoS ONE, Vol 8, Iss 4, p e62295 (2013)

Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product, Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of

Externí odkaz: https://doaj.org/article/f9a0fd8880214c629ade8f4eb736a565

NMR structure of the Wnt modulator protein Sclerostin

Autor: Peter Schmieder, Werner Schmitz, Stella E. Weidauer, Hartmut Oschkinat, Thomas D. Mueller, Monika Beerbaum

Publikováno v: Biochemical and Biophysical Research Communications. 380:160-165

Sclerostin has been identified as a negative regulator of bone growth. Initially it was considered that Sclerostin performs its regulatory function via acting as a modulator of bone morphogenetic proteins (BMPs) similar to known examples such as Nogg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d583c6e8be8812baae7611bb846f567
https://doi.org/10.1016/j.bbrc.2009.01.062

The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6

Autor: Achim Knappik, Stella E. Weidauer, J. W. Back, Monika Beerbaum, Eva-Maria Muth, Thomas D. Mueller, Peter Schmieder, K. van Pee, Verena Boschert, Peter Timmerman, Christian Frisch

Publikováno v: Open Biology, Vol 6, Iss 8 (2016)
Open biology, 6(8):160120
Open Biology

The glycoprotein sclerostin has been identified as a negative regulator of bone growth. It exerts its function by interacting with the Wnt co-receptor LRP5/6, blocks the binding of Wnt factors and thereby inhibits Wnt signalling. Neutralizing anti-sc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46acbedb0e10d4a8ab7bcc9b4a53bc57
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/17792

Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling

Autor: Thomas D. Mueller, Christian Frisch, Maarten van Dinther, Peter ten Dijke, Eva-Maria Muth, Verena Boschert, Juan Zhang, Achim Knappik, Stella E. Weidauer, Puck B. van Kasteren, David J. J. de Gorter

Publikováno v: PLoS ONE
PLoS ONE, 8(4)
PLoS ONE, Vol 8, Iss 4, p e62295 (2013)

Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product, Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb43fcf95cf450089b54f1eba6cb9523
https://pubmed.ncbi.nlm.nih.gov/23638027

First missense mutation in the **SOST** gene causing sclerosteosis by loss of sclerostin function

Autor: Elke Piters, Socrates E. Papapoulos, Wim Van Hul, Rutger L. van Bezooijen, Karen Jennes, Cavit Culha, Thomas D. Mueller, Jean-Pierre Timmermans, Stella E. Weidauer, Martiene Moester, Clemens W.G.M. Löwik, Dirk Adriaensen, Fenna de Freitas

Publikováno v: Human mutation
Human Mutation; Vol 31
Human Mutation
Human Mutation, Wiley, 2010, 31 (7), ⟨10.1002/humu.21274⟩
Human Mutation, 31(7), E1526E1543

Sclerosteosis is a rare bone dysplasia characterized by greatly increased bone mass, especially of the long bones and the skull. Patients are tall, show facial asymmetry and often have syndactyly. Clinical complications are due to entrapment of crani

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::516ce22fb89c98a81af8f6a49ceae3c0
https://hdl.handle.net/10067/842190151162165141